Key result
Discharge neurohormonal blockade shows a trend toward lower mortality in HeartMate 3 LVAD recipients.
Why the study?
The use of neurohormonal blockade around index discharge and its impact on outcomes in HeartMate 3 LVAD recipients remained undefined.
Does neurohormonal blockade prescription at discharge improve survival and reduce heart failure readmission in HeartMate 3 LVAD recipients?
Cohort (n=273)
No
Does neurohormonal blockade prescription at discharge improve survival and reduce heart failure readmission in HeartMate 3 LVAD recipients?
Answers are grounded in this paper and cite their sources.
Early initiation of neurohormonal blockade at discharge after HeartMate 3 LVAD implantation shows a trend toward improved survival, highlighting a potential opportunity for optimizing post-implant medical therapy.
Background The use of neurohormonal blockade (NB) including beta blockers, renin angiotensin inhibitors (RASIs), and mineralocorticoid receptor antagonists (MRAs) in patients after left ventricular assist device (LVAD) implantation has been associated with improved clinical outcomes. However, its use during and soon after index discharge (LVAD implant admission), a period of potential hemodynamic and laboratory vulnerability, and impact on outcomes in HeartMate 3 (HM3) recipients remains undefined. Purpose This study aimed to characterize index HeartMate 3 (HM3) LVAD recipients who were given a prescription for NB at discharge and determine its clinical impact. Methods A single-center retrospective analysis was performed of patients who underwent HM3 LVAD implantation from January 1, 2015, to December 31, 2021. To align with contemporary definitions, we included sodium-glucose cotransporter 2 inhibitors (SGLT-2i) in the NB cohort. Patients on and not on any NB after index discharge were compared. Cox proportional hazards modeling was performed to investigate the association between the presence of NB with survival and heart failure (HF) readmission. Results 273 patients underwent HM3 implantation during the study period. The average implant age was 58 years, 75% were men, and 78% were Black patients. Of the 273 patients, 138 (50%) had a prescription of at least one NB agent after index discharge. RASIs were the most prescribed after index discharge (42%), followed by MRAs (17%), beta blockers (3.7%), and SGLT-2i (3.3%) (Table). Predictors of NB use include discharge creatinine (HR 0.5; 95% CI, 0.28 - 0.92; p=0.026), hemoglobin (HR 1.33; 95% CI, 1.06 - 1.67; p=0.012) and history of stroke (HR 0.42; 95% CI, 0.21 - 0.88; p=0.021). Patients who received NB at index discharge had longer survival compared to those who did not at a median follow-up of 3.8 years (Figure). Multivariate adjustment demonstrated a trend towards a lower risk of mortality in HM3 LVAD recipients who received NB at discharge (HR 0.69; 95% CI, 0.44-1.09; p=0.11). A discharge prescription for NB was not associated with HF readmission. Conclusion Implementation of NB remains an opportunity for improvement in the care of HM3 LVAD recipients. Our findings suggest that despite the concerns of labile changes in clinical status, early initiation of NB appears to have a beneficial signal, acknowledging that there may be clinical factors that influence initiation of NB that are also prognostic. Further studies are needed to examine whether an aggressive, upfront implementation of NB during index hospitalization will improve clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Frisancho et al. (2025) conducted a cohort in HeartMate 3 LVAD recipients (n=273). Neurohormonal blockade (NB) prescription at discharge vs. No neurohormonal blockade prescription at discharge was evaluated on Mortality (HR 0.69, 95% CI 0.44-1.09, p=0.11). A discharge prescription for neurohormonal blockade in HeartMate 3 LVAD recipients showed a trend toward lower mortality risk compared to no prescription.
Synapse has enriched 10 related papers. Consider them for comparative context: